Chronic constipation and treatment options (Review)

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 3-8

  El Salhy, Magdy ^a,c   Svensen, Rune ^b   Hatlebakk, Jan Gunnar ^c   Gilja, Odd Helge ^c   Hausken, Trygve ^c  

^a Stord Hospital   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Functional constipation; Guanylin peptide; Linaclotide; Pruclopride; Receptor agonist; Serotonin

Indexed keywords

CHRONIC DISEASE; CONSTIPATION; HUMANS; LAXATIVES; NEUROSECRETORY SYSTEMS;

EID: 84893826041     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1770     Document Type: Review

References (53)

1. Woodward S: Assessment and management of constipation in older people. Nurs Older People 24: 21-26, 2012
2. Pare P: The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can J Gastroenterol 25 Suppl B: 36B-40B, 2011
3. Lacy BE, Levenick JM and Crowell M: Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol 5: 233-247, 2012
4. Peppas G, Alexiou VG, Mourtzoukou E and Falagas ME: Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 8: 5, 2008
5. Sanchez MI and Bercik P: Epidemiology and burden of chronic constipation. Can J Gastroenterol 25 Suppl B: 11B-15B, 2011
6. Irvine EJ, Ferrazzi S, Pare P, Thompson WG and Rance L: Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 97: 1986-1993, 2002
7. Sun SX, Dibonaventura M, Purayidathil FW, Wagner JS, Dabbous O and Mody R: Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 56: 2688-2695, 2011
8. Everhart JE and Ruhl CE: Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 136: 741-754, 2009.
9. Sandler RS, Everhart JE, Donowitz M, et al: The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500-1511, 2002.
10. Cheng C, Chan AO, Hui WM and Lam SK: Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study. Aliment Pharmacol Ther 18: 319-326, 2003.
11. Mason HJ, Serrano-Ikkos E and Kamm MA: Psychological state and quality of life in patients having behavioral treatment (biofeedback) for intractable constipation. Am J Gastroenterol 97: 3154-3159, 2002.
12. Haug TT, Mykletun A and Dahl AA: Are anxiety and depression related to gastrointestinal symptoms in the general population? Scand J Gastroenterol 37: 294-298, 2002.
13. Martin BC, Barghout V and Cerulli A: Direct medical costs of constipation in the United States. Managed care interface 19: 43-49, 2006.
14. Nyrop KA, Palsson OS, Levy RL, et al: Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 26: 237-248, 2007.
15. Choung RS, Branda ME, Chitkara D, et al: Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 33: 251-260, 2011.
16. McCrea GL, Miaskowski C, Stotts NA, Macera L and Varma MG: Pathophysiology of constipation in the older adult. World J Gastroenterol 14: 2631-2638, 2008.
17. Sandström O and El-Salhy M: Ageing and endocrine cells of human duodenum. Mech Ageing Dev 108: 39-48, 1999.
18. Sandström O and El-Salhy M: Human rectal endocrine cells and aging. Mech Ageing Dev 108: 219-226, 1999.
19. Quigley EM: Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol 5: 23-30, 2012.
20. Krishnamurthy S, Schuffler MD, Rohrmann CA and Pope CE II: Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 88: 26-34, 1985.
21. Schouten WR, ten Kate FJ, de Graaf EJ, Gilberts EC, Simons JL and Klück P: Visceral neuropathy in slow transit constipation: an immunohistochemical investigation with monoclonal antibodies against neurofilament. Dis Colon Rectum 36: 1112-1117, 1993.
22. Wedel T, Roblick UJ, Ott V, et al: Oligoneuronal hypoganglionosis in patients with idiopathic slow-transit constipation. Dis Colon Rectum 45: 54-62, 2002.
23. Park HJ, Kamm MA, Abbasi AM and Talbot IC: Immunohistochemical study of the colonic muscle and innervation in idiopathic chronic constipation. Dis Colon Rectum 38: 509-513, 1995.
24. El-Salhy M and Norrgård O: Colonic neuroendocrine peptide levels in patients with chronic idiopathic slow transit constipation. Ups J Med Sci 103: 223-230, 1998.
25. Sjölund K, Ekman R, Akre F and Lindner P: Motilin in chronic idiopathic constipation. Scand J Gastroenterol 21: 914-918, 1986.
26. Sjölund K, Fasth S, Ekman R, et al: Neuropeptides in idiopathic chronic constipation (slow transit constipation). Neurogastroenterol Motil 9: 143-150, 1997.
27. Preston DM, Adrian TE, Christofides ND, Lennard-Jones JE and Bloom SR: Positive correlation between symptoms and circulating motilin, pancreatic polypeptide and gastrin concentrations in functional bowel disorders. Gut 26: 1059-1064, 1985.
28. Tomita R, Fujisaki S, Ikeda T and Fukuzawa M: Role of nitric oxide in the colon of patients with slow-transit constipation. Dis Colon Rectum 45: 593-600, 2002.
29. Tomita R, Tanjoh K, Fujisaki S, Ikeda T and Fukuzawa M: Regulation of the enteric nervous system in the colon of patients with slow transit constipation. Hepatogastroenterol 49: 1540-1544, 2002.
30. El-Salhy M, Norrgård O and Spinnell S: Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol 34: 1007-1011, 1999.
31. El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG and Hausken T: The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med 29: 723-731, 2012.
32. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 4: 2783-2800, 2012.
33. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 57: 873-878, 2012.
34. El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T (eds): Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. 1st edition. Nova Science Publishers, Inc., New York, 2012.
35. Tack J, Müller-Lissner S, Stanghellini V, et al: Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil 23: 697-710, 2011.
36. Ostgaard H, Hausken T, Gundersen D and El-Salhy M: Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. Mol Med Rep 5: 1382-1390, 2012.
37. Johannesson E, Simrén M, Strid H, Bajor A and Sadik R: Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 106: 915-922, 2011.
38. Chey WD and Rai J: Exercise and IBS: no pain, no gain. Gastroenterology 141: 1941-1943, 2011.
39. Strid H, Simrén M, Störsrud S, Stotzer PO and Sadik R: Effect of heavy exercise on gastrointestinal transit in endurance athletes. Scand J Gastroenterol 46: 673-677, 2011.
40. Wang Y, Kondo T, Suzukamo Y, Oouchida Y and Izumi S: Vagal nerve regulation is essential for the increase in gastric motility in response to mild exercise. Tohoku J Exp Med 222: 155-163, 2010.
41. Whelan K: Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 14: 581-587, 2011.
42. Whorwell PJ: Do probiotics improve symptoms in patients with irritable bowel syndrome? Therap Adv Gastroenterol 2: 37-44, 2009.
43. Spiller R: Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 28: 385-396, 2008.
44. Aragon G, Graham DB, Borum M and Doman DB: Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (NY) 6: 39-44, 2010.
45. El-Salhy M, Lillebø E, Reinemo A, Salmelid L and Hausken T: Effects of a health program comprising reassurance, diet management, probiotics administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. Gastroenterology Insights 2: 21-26, 2010.
46. Spiller RC: Upper gut dysmotility in slow-transit constipation: is it evidence for a pan-enteric neurological deficit in severe slow transit constipation? Eur J Gastroenterol Hepatol 11: 693-696, 1999.
47. Quigley EM, Vandeplassche L, Kerstens R and Ausma J: Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29: 315-328, 2009.
48. Tack J, Camilleri M, Chang L, et al: Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35: 745-767, 2012.
49. Ke M, Zou D, Yuan Y, et al: Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 24:999-e541, 2012.
50. Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P and Vandeplassche L: Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 32: 1113-1123, 2010.
51. Camilleri M, Beyens G, Kerstens R, Robinson P and Vandeplassche L: Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 21: 1256-e1117, 2009.
52. Johnston JM, Shiff SJ and Quigley EM: A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr Med Res Opin 29: 149-160, 2013.
53. Emmanuel A: Current management strategies and therapeutic targets in chronic constipation. Therap Adv Gastroenterol 4: 37-48, 2011.